Clinical Trials Logo

Clinical Trial Summary

The aim of this work is to investigate the expression of the bitter taste receptors in p16-positive and negative oropharyngeal carcinomas (in comparison to healthy, local tissue).


Clinical Trial Description

Goal setting The aim of this work is to investigate the expression of the bitter taste receptors in p16-positive and negative oropharyngeal carcinomas (in comparison to healthy, local tissue). The hypothesis is that oropharyngeal carcinomas express TAS2Rs and that their stimulation can induce apoptosis. The lower expression of certain TAS2Rs in the tumor cells could represent protection from apoptosis by stimulation with the bitter ligands. Alternatively, it could polymorphisms of the bitter taste receptors, which can influence their function independently of the expression. In order to address the question of general bitter sensitivity in more detail, the investigators are planning to carry out a bitter taste test on the test subjects. methodology As this is a pilot study, the investigators limit the number of subjects to 10 patients with p-16 positive and negative oropharyngeal squamous cell carcinoma and 10 patients with acute recurrent tonsillitis or other benign pathology in pharynx. The expression analysis is carried out using qPCR and possibly immunohistochemical methods. Taste strips are used for the taste tests. Cognitive interest The results of this study will provide important insight into the pathophysiology of oropharyngeal cancers and possibly all TAS2R-expressing cancers. In addition, this and further studies can create a theoretical basis for new therapeutic methods for this group of diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05211427
Study type Interventional
Source Technische Universität Dresden
Contact
Status Recruiting
Phase N/A
Start date March 23, 2021
Completion date April 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Recruiting NCT04567082 - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Recruiting NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Active, not recruiting NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05307939 - A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) Phase 2
Completed NCT00158652 - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Phase 3
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Recruiting NCT03383094 - Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Phase 2